Cardiovascular disease (CVD) risk in type 2 diabetes (T2DM) is only partially reduced by
intensive glycemic control. Diabetic dyslipidemia is suggested to be an additional important …

Comparative‐effectiveness research (CER) aims to produce actionable evidence regarding
the effectiveness and safety of medical products and interventions as they are used outside …

Aim As there have been concerns that some classes or agents for the treatment of type 2
diabetes may increase CV risk, we evaluated the cardiovascular profile of the dipeptidyl …

Subcutaneous exenatide extended-release (ER; Bydureon™; also known as exenatide
once weekly), a glucagon-like peptide-1 receptor agonist, provides a convenient, simple …

The endothelium is critical for multiple processes occurring on both sides of the vascular
wall including regulation of blood flow, maintenance of blood fluidity and control of …

Despite a better understanding of cardiovascular risk factors and attempts at optimal
management, diabetes-related macrovascular events remain a significant cause of morbidity …

Diabetes mellitus is a prevalent chronic disease characterized by hyperglycemia. Diabetic
peripheral neuropathy (DPN) is one of the complications of diabetes mellitus and is caused …

Biopharmaceutical companies have increasingly been exploring Quantitative Systems
Pharmacology (QSP) as a potential avenue to address current challenges in drug …

Type 2 diabetes remains an escalating problem worldwide, despite a range of treatments
being available. The revelation that insulin secretion is under the control of a gut hormone …

Objective No clinical trials have been conducted to directly compare the effect of the two
high-intensity statins, rosuvastatin and atorvastatin, on cardiovascular outcomes. However …